Ancitabine
Based on 1 publication(s) in Google Scholar
Ancitabine (Cyclocytidine) is a cytarabine derivative that inhibits viral replication. Ancitabine blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 31698-14-3
- Formule: C9H11N3O4
- Masse moléculaire:225.20
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ancitabine
MoreVoir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Description
In Vitro
Ancitabine non-toxically inhibits vaccinia virus replication in BSC40 African green monkey kidney cells with a 48 h IC99 of 11 μM, acting by blocking viral DNA replication and preventing progression from early to late viral protein synthesis[1].
Ancitabine (5 μg/mL; 2 days) completely inhibits replication of the KOS strain of HSV-1 in HEL cells[2].
Ancitabine (5 μg/mL; 2 days) completely inhibits replication of the Savage strain of HSV-2 in HEL cells[2].
Ancitabine (0.14-10 μg/mL; 4 days) potently inhibits replication of the AD169 strain of HCMV in HEL cells, with an ED90 of 0.14 μg/mL and complete inhibition at 10 μg/mL maintained for 4 days[2].
Ancitabine (<0.010->100 μg/mL; 4 days) is non-toxic to stationary HEL cells at concentrations up to 100 μg/mL, but is highly cytotoxic to growing HEL cells with a CyD50 of <0.010 μg/mL[2].
Ancitabine (500 μM; 48 h) is converted to its triphosphate form in HCMV-infected HEL cells[2].
Ancitabine (5 μg/mL; 48 h) substantially suppresses synthesis of HCMV DNA in infected HEL cells[2].
Ancitabine (10 μM; 72 h) induces intracellular vesicle formation in human colorectal carcinoma HCT116 cells with reproducible morphological profiles[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 31698-14-3
-
Masse moléculaire 225.20
-
Formule C9H11N3O4
-
SMILES
OC[C@@H]1[C@@H](O)[C@@](O2)([H])[C@@](N(C2=N3)C=CC3=N)([H])O1
-
Synonyms
Cyclocytidine; Cyclo-CMP
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
Pureté et documentation
Références
[1]. Deng L, et al. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol. 2007;81(24):13392-13402. [Content Brief]
[2]. Nakamura K, et al. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. J Med Virol. 1990;31(2):141-147. [Content Brief]
[3]. Aftab O, et al. Detection of cell aggregation and altered cell viability by automated label-free video microscopy: a promising alternative to endpoint viability assays in high-throughput screening. J Biomol Screen. 2015;20(3):372-381. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Ancitabine
- 31698-14-3
- Cyclocytidine
- Cyclo-CMP
- DNA/RNA Synthesis
- Orthopoxvirus
- CMV
- Autophagy
- cytidine deaminase
- leukemia
- cytarabine
- human colorectal carcinoma cells
- human fibroblasts
- human cytomegalovirus
- BSC40 African green monkey kidney cells
- HCT116 cells
- herpes simplex virus types 1 and 2
- vaccinia virus
- Inhibitor
- inhibitor
- inhibit